Diametric Capital’s Contineum Therapeutics CTNM Stock Holding History

Diametric Capital’s Portfolio CTNM Stock Details CTNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-10,729	Closed	-$140K	–	721
2026 Q1	$140K	Buy	+10,729	New	+$144K	0.04%	403

Other funds holding CTNM

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Diametric Capital's CTNM Position: Q2 2026 in Review

Diametric Capital sold out of Contineum Therapeutics (CTNM) in Q2 2026, closing a stake of 10,729 shares — an estimated $140K sold.

Diametric Capital first reported a position in CTNM in Q1 2026 and held it in 1 quarter. The position peaked at $140K in Q1 2026. 102 funds tracked by Wall St. Rank hold CTNM as of Q2 2026.

Diametric Capital reported no remaining Contineum Therapeutics position as of Q2 2026 after selling out during the quarter.
Diametric Capital sold 10,729 Contineum Therapeutics shares in Q2 2026, an estimated $140K.
Diametric Capital first reported a position in Contineum Therapeutics in Q1 2026 and held it in 1 quarter.
Diametric Capital's Contineum Therapeutics position peaked at $140K in Q1 2026.
102 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2026.

Based on Diametric Capital's 13F filing for Q2 2026, filed 14 Aug 2026.